Skip to main content
Premium Trial:

Request an Annual Quote

Nanogen to Record $50M-$60M Charge in Q4 Related to Epoch Acquisition

NEW YORK, Feb. 14 (GenomeWeb News) - Nanogen will record a non-cash accounting charge of between $50 million and $60 million for the quarter ended Dec. 31 relating to a change in goodwill accounting as part of its December 2004 acquisition of Epoch Biosciences.


The company said an increase in Nanogen's stock price between the day the acquisition deal was signed and the day it closed was a "significant factor" in the adjustment, according to a statement filed yesterday with the US Securities and Exchange Commission .


Nanogen said the stock-based valuation of the transaction increased by approximately $35 million.


The company expects to announce "within a week" a date for its fourth-quarter earnings release.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.